期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗造血系统肿瘤抗体的特点、用法和毒副作用 被引量：1

Characteristics,Usages and Side Effects of Antibodies Against Haematopoietic Malignancy
下载PDF
导出
摘要 抗体治疗为复发和难治性造血系统肿瘤提供了一种新的选择。目前被批准治疗造血系统肿瘤的抗体有5个。本文介绍了这5种抗体的特点、用法和毒副作用。Rituximab是人／鼠嵌合抗体,Gemtuzumab和Alemtuzumab为人源化抗体,而Ibritumomab和Tositumomab是小鼠抗体与放射性毒素连接物。这些治疗性抗体的毒副作用为可逆性,病人大多可耐受,主要包括输液反应、肿瘤溶解综合征、骨髓抑制等。
作者 王惠琴 孙卫民
机构地区 上海理工大学医疗器械学院 第二军医大学免疫学研究所
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2005年第4期312-314,共3页 Chinese Journal of Cancer Biotherapy
关键词 淋巴瘤 白血病 抗体治疗 用法 毒副作用
分类号 R392.11 [医药卫生—免疫学]
  • 相关文献

参考文献8

  • 1范冬梅,刘银星,熊冬生,赖增祖,许元富,邵晓枫,杨铭,杨纯正.嵌合抗CD20Fab′抗体片段诱导Raji细胞的凋亡机制[J].中国肿瘤生物治疗杂志,2003,10(3):166-169. 被引量：1
  • 2王玉刚,沈倍奋.CD20抗原及治疗性抗CD20抗体[J].中国肿瘤生物治疗杂志,2005,12(1):76-79. 被引量：10
  • 3Cersosimo RJ. Monoclonal antibodies in the treatment of cancer,part1, part 2[J]. Am J Health-Syst Pharm. 2003, 60(5) : 1531-48, 1631-1643.
  • 4Kaminski MS, Tuck M, Estes J, et al. ^131Ⅰ-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma[ J ]. N Engl J Med,2005, 352(5) : 441-449.
  • 5Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin[ J ]. Curr Opin Pharmacol, 2003, 3(4) : 386-390.
  • 6Sievers EL. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg) [J]. Blood Cells,Molecules, and Diseases, 2003, 31 ( 1 ) : 7-10.
  • 7Keating M J, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab ( Campath-1 H) in patients who have failed fludarabine: Results of a large international study [ J ]. Blood, 2002, 99 ( 8 ) : 3554-3561.
  • 8Rai K, Coutre S, Rizzieri D, et al. Efficacy and safety of Almetuzumab (Campath-1H ) in refractory B-CLL patients treated on a compassionate basis[ J ]. Blood, 2001, 98 (1): 365a.

二级参考文献28

  • 1Golay .IT, Clark EA, Beverley PC, et d. The CD20 ( BP35 ) antigen is involved in activation of B cell from the G0 to the G1 phase of the cell cycle[J]. J Immunol, 1985, 135: 3795-3801.
  • 2Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophoblc protein with multiple tramsmembrane domains[ J]. EMBO J, 1988, 7:711-717.
  • 3Liu AY, Robinson RJ, Murvay ED, et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity[J]. J Immunol, 1987, 139: 3521-3526.
  • 4Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies[J]. Cancer Res, 1989, 49: 4906-4912.
  • 5Preess OW, Howell-Clark J, Andereson S, et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cell[ J].Blood, 1994, 83: 1390-1397.
  • 6Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody[J]. Curr Opin Oncol, 1998, 10: 548-551.
  • 7Beiske H, Clark EA, Holte H, et al. Triggering of neoplastic B cells via surface IgM and the cell surface antigen CIY20 and CD40.Responses differ from normal blood B cells and are restricted to certain morphottogic subsets[J]. Int J Cancer, 1988, 42: 521-528.
  • 8ReffME, Carner K, Chambers KS, et al. Depletion of B cell in vivo by a chimeric mouse human monolona antibody to CD20[ J].Blood, 1994, 83: 435-445.
  • 9Tedder TF, McIntyre G, Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes[J]. Mol Immunol, 1988, 25(12): 1321-1330.
  • 10Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: Signaling through lipid rafts[J]. Immunology, 2002, 107(2): 176-182.

共引文献9

同被引文献7

  • 1王玉刚,沈倍奋.CD20抗原及治疗性抗CD20抗体[J].中国肿瘤生物治疗杂志,2005,12(1):76-79. 被引量：10
  • 2Gordan LN,Grow WB,Pusateri A,et al.Phase Ⅱ trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders[J].J Clin Oncol,2005,23 (6):1096-1102.
  • 3Hainsworth JD,Litchy S,Shaffer DW,et al.Maximizing therapeutic benefit of rituximab:Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase Ⅱ trial of the Minnie Pearl Cancer Research Network[J].J Clin Oncol,2005,23(6):1088-1095.
  • 4Rummel MJ,Al-Batran SE,Kim SZ,et al.Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma[J].J Clin Oncol,2005,23 (15):3383-3389.
  • 5Hainsworth JD,Litchy S,Morrissey LH,et al.Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-hodgkin's lymphoma:A phase Ⅱ trial of the minnie pearl cancer research network[J].J Clin Oncol,2005,23(7):1500-1506.
  • 6Marcus R.Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma[J].Semin Oncol,2005,32(1 Pt 2):36-43.
  • 7Grillo-Lopez AJ.90Y-ibritumomab tiuxetan:Rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma[J].Semin Oncol,2005,32(1 Pt 2):44-49.

引证文献1

中国肿瘤生物治疗杂志
2005年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部